Interpace Biosciences

About:

Interpace Biosciences is a leading health care commercialization company.

Top Investors: Ampersand Capital Partners, 1315 Capital

Description:

Interpace Biosciences (IDXG) is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. Their Interpace Diagnostics business unit provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services, including such widely respected tests as PancraGen®, ThyGeNext®, ThyraMir®, RespriDX® and BarreGen®.

Total Funding Amount:

$70.1M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Hamilton, Waikato, New Zealand

Founded Date:

1986-01-01

Founders:

Number of Employees:

501-1000

Last Funding Date:

2020-01-13

IPO Status:

Public

Industries: